

**Oxford BioDynamics plc**  
("Oxford BioDynamics" or "OBD" or the "Company")

**Prostate Cancer Research NHS screening report highlights OBD's EpiSwitch PSE**

- Report concludes that a targeted prostate cancer UK screening programme is currently feasible
- Emerging technologies, including EpiSwitch PSE, should be considered in the NHS
- PSE recognised for its strong potential to cut false positives and minimise diagnostic procedures

**Oxford, UK - 14 October 2025** - Oxford BioDynamics Plc (AIM: OBD), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, notes the publication today of "*Prostate Cancer Screening: The Impact on the NHS*," a new report by prominent UK charity Prostate Cancer Research (PCR)<sup>1</sup>.

The report concludes that targeted prostate cancer screening in the UK is practical, and that the UK National Screening Committee (NSC) should recommend a national programme for screening prostate cancer in high-risk men aged 45-69.

Furthermore, the report makes the case that new screening technologies, such as the [EpiSwitch PSE](#) blood test from Oxford BioDynamics, should be considered in the NHS as they promise greater accuracy, fewer unnecessary procedures, and can form the foundation for a population-wide programme. EpiSwitch PSE is named in the report, highlighting its strong potential to reduce false positives and minimise the need for further diagnostic procedures in low-risk cases.

The publication includes modelling for a future screening programme, which shows that adopting a reflex test with a balanced high specificity and sensitivity could reduce anticipated demand on MRI by more than 86% and biopsy procedures by 84%, while also saving costs for the NHS.

**Iain Ross, Executive Chariman of Oxford BioDynamics, said:**

*"We welcome the conclusions of this timely report, which demonstrates that the technologies and systems are now in place to make prostate cancer screening both feasible and effective to reduce inequalities and save lives.*

*"The findings recognise that our EpiSwitch PSE blood test, with its unmatched 97% specificity, could significantly reduce unnecessary MRIs and biopsies, and therefore help to make large-scale screening a practical reality for the NHS. This is consistent with the real-world data recently published showing PSE can enable clinics to safely avoid biopsies in up to 79% of patients with an elevated PSA<sup>2</sup>."*

The report will be presented this afternoon at Prostate Cancer Research's Parliamentary Reception in the House of Commons. The event is sponsored by Calvin Bailey MBE MP, Rt Hon David Lammy FRSA MP, and former prime minister Rt Hon Rishi Sunak MP.

-Ends-

**References**

<sup>1</sup> Prostate Cancer Research. Prostate Cancer Screening: The Impact on the NHS. Evaluating the demand, costs and delivery of a national prostate cancer screening programme in the UK. October 2025. <https://www.prostate-cancer-research.org.uk>

<sup>2</sup> Berghausen, J. et al. (2025). EpiSwitch PSE Blood Test Reduces Unnecessary Prostate Biopsies: A Real-World Clinical Utility Study. Cancers. <https://doi.org/10.3390/cancers17132193>

**For further information please contact:**

**Oxford BioDynamics Plc**

+44 (0)1865 518910

Iain Ross, Executive Chairman

Paul Stockdale, CFO

**Camarco - Financial PR**

Marc Cohen / Tilly Butcher / Fergus Young

+44 (0)20 3757 4980

[OBDFinancial@camarco.co.uk](mailto:OBDFinancial@camarco.co.uk)

**Notes for Editors**

**About Oxford BioDynamics Plc**

Oxford BioDynamics Plc (AIM: OBD) is an international biotechnology company, advancing personalized healthcare by developing and commercializing precision clinical diagnostic tests for life-changing diseases.

Currently OBD has two commercially available products: the [EpiSwitch® PSE](#) (EpiSwitch Prostate Screening test) and [EpiSwitch® CIRT](#) (Checkpoint Inhibitor Response Test) blood tests. PSE boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer. CIRT is a highly accurate (85%) predictive response test to immuno-oncology checkpoint inhibitor treatments.

The tests are based on OBD's proprietary 3D genomic biomarker platform, EpiSwitch® which enables screening, evaluation, validation and monitoring of biomarkers to diagnose patients or determine how individuals might respond to a disease or treatment.

OBD's clinical smart tests have the potential to be used across a broader range of indications, and new tests are being developed in the areas of oncology, neurology, inflammation, hepatology and animal health.

The Group's headquarters and UK laboratories are in Oxford, UK. Its US operations and clinical laboratory are in Maryland, USA, along with a reference laboratory in Penang, Malaysia.

OBD is listed on the London Stock Exchange's AIM (LSE: OBD). For more information, please visit the Company's website, [www.oxfordbiodynamics.com](http://www.oxfordbiodynamics.com), X (@OxBioDynamics) or [LinkedIn](#).

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAGPGPPUUPAGQW